Article

Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of israeli patients: outcome and associated factors.

The Israel Medical Association journal: IMAJ (Impact Factor: 0.9). 06/2014; 16(6):347-51.
Source: PubMed

ABSTRACT The VEGFR/PDGFR inhibitor sunitinib was approved in Israel in 2008 for the treatment of metastatic renal cell carcinoma (mRCC), based on an international trial. However, the efficacy of sunitinib treatment in Israeli mRCC patients has not been previously reported.

0 Bookmarks
 · 
26 Views

Avivit Peer